Lung Cancer Therapeutics Market Size, Share, Growth Analysis, By Cancer type(Non-Small Cell Lung Cancer, Metastatic Lung Cancer), By Molecule Type(Small Molecules, Biologics), By Treatment Type(Chemotherapy, Radiation Therapy), By End Use(Hospitals, Homecare) - Industry Forecast 2024-2031

The top market participants have a wide geographic reach and a wide range of products to meet a variety of consumer wants. Industry players are spending a lot of money on R&D in order to introduce new Treatment and increase their profitability in this potential market

Lung Cancer Therapeutics Market Top Player’s Company Profiles

• AstraZeneca plc
• F. Hoffmann-La Roche AG
• Bristol-Myers Squibb Company
• Merck & Co., Inc.
• Pfizer Inc.
• Novartis International AG
• Eli Lilly and Company
• Boehringer Ingelheim International GmbH
• Takeda Pharmaceutical Company Limited
• AbbVie Inc.
• Sanofi S.A.
• Astellas Pharma Inc.
• Celgene Corporation
• Eisai Co., Ltd.
• Johnson & Johnson
• Bayer AG
• AbbVie Inc.
• GlaxoSmithKline plc
• Amgen Inc.
• Spectrum Pharmaceuticals, Inc.

Lung Cancer Therapeutics Market Recent Development

• In March 2022, AstraZeneca, PATH, and Qure.ai have teamed up to improve lung health in low- and middle-income countries. These three companies will collaborate to create a framework for using cutting-edge artificial intelligence technologies to detect lung cancer in patients undergoing chest screening for tuberculosis.
• In March 2022, Duke University has joined Known Medicine, a rapidly expanding biotechnology company that specializes in finding potent anticancer medications, to determine the efficacy of the drugs for patients with lung cancer. Through this agreement, Known Medicine will be able to evaluate and improve their ODINTM platform. Both parties want to assess the platform's ability to predict clinical outcomes accurately in about 75 patients.